Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?

Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outperformance, experts advise against heavy sectoral bets, recommending a 5% to 10% satellite allocation via SIPs while navigating potential long-term US tariff developments.